Medical Pharmacology: Chapter: CHF — Chapter 10 -- Module: CHF-04 — Loop Diuretics, Aldosterone Antagonists, and Diuretic Resistance

Chapter: CHF — Chapter 10 — Module: CHF-04 — Loop Diuretics, Aldosterone Antagonists, and Diuretic Resistance
Tier: T3

1. A 79-year-old man with HFrEF (LVEF 22%) and stage 3b CKD (eGFR 31 mL/min/1.73m²) is admitted with severe decompensation. He is cool and clammy with narrow pulse pressure, his estimated cardiac output is severely reduced, and serum albumin is 2.6 g/dL. He has been on furosemide 160 mg twice daily for 22 months. Despite IV furosemide 240 mg twice daily for 36 hours, urine output is 20–30 mL/hour. His physician identifies three simultaneous mechanisms of diuretic resistance. Which of the following correctly identifies all three and explains how they converge in this patient?

A) Braking phenomenon from 22 months of furosemide causing NCC upregulation in the distal convoluted tubule; NSAID-mediated prostaglandin inhibition blunting renal vasodilation and furosemide's venodilatory effect; and loop diuretic-induced metabolic alkalosis reducing NKCC2 proton-coupled cotransport efficiency at the thick ascending limb
B) Hypoalbuminemia reducing the protein-bound fraction of furosemide available for OAT1/OAT3 tubular secretion; braking phenomenon from NCC upregulation attenuating net natriuresis despite luminal NKCC2 blockade; and NSAID-mediated prostaglandin inhibition reducing renal blood flow — together these three require sequential nephron blockade, albumin infusion, and NSAID discontinuation as a triple intervention
C) Reduced GFR limiting glomerular filtration of furosemide to the tubular lumen; CKD-related NKCC2 downregulation reducing the pharmacological target density at the thick ascending limb; and hypoalbuminemia causing furosemide to redistribute into extravascular tissue compartments, preventing adequate plasma concentrations for tubular secretion
D) Low cardiac output reducing renal blood flow and peritubular capillary delivery of the albumin-furosemide complex to OAT1/OAT3 secretion sites, impairing tubular furosemide delivery; accumulated uremic organic acids competing with furosemide for OAT1/OAT3 transport given his eGFR of 31 mL/min/1.73m²; and the braking phenomenon from 22 months of furosemide producing distal tubule NCC upregulation that reclaims an increasing fraction of the sodium NKCC2 blockade delivers distally — all three reduce the net natriuresis from any given furosemide dose
E) Hypoalbuminemia forming albumin-furosemide complexes that are too large to be secreted by OAT1/OAT3 transporters; CKD-related reduction in tubular fluid pH increasing furosemide ionization and trapping it in the tubular lumen before it can bind the luminal face of NKCC2; and the braking phenomenon reducing NKCC2 expression in the thick ascending limb through transcriptional downregulation driven by chronic blockade

ANSWER: D

Rationale:

This patient has three well-established, simultaneous mechanisms of diuretic resistance that all converge to reduce the net natriuretic effect of furosemide. First, low cardiac output: severely reduced cardiac output decreases renal blood flow, impairing the rate at which the albumin-furosemide complex in peritubular capillary blood is delivered to the OAT1 and OAT3 transporters in the proximal tubule; reduced delivery means reduced tubular secretion of furosemide into the lumen and lower luminal concentrations at NKCC2. Second, CKD-related organic acid competition: at eGFR of 31 mL/min/1.73m², uremic solutes including hippurate, indoxyl sulfate, and p-cresyl sulfate accumulate and compete with furosemide for OAT1/OAT3 transport — directly reducing the rate of furosemide secretion independent of the perfusion deficit. Third, the braking phenomenon: 22 months of furosemide exposure has produced compensatory hypertrophy of distal convoluted tubule cells with NCC upregulation, allowing the distal nephron to reclaim an increasing fraction of the sodium delivered past the loop. Together, these three mechanisms are additive: less furosemide reaches NKCC2 (mechanisms 1 and 2), and the sodium that does escape NKCC2 blockade is increasingly recaptured distally (mechanism 3). Rational management addresses all three: optimize cardiac output through GDMT review; consider dose escalation or switch to continuous infusion to compensate for impaired delivery; add metolazone for sequential nephron blockade to overcome NCC upregulation.

Option A: Option A is incorrect: NSAIDs are not listed in this patient's medications, and there is no basis for NSAID-mediated prostaglandin inhibition here; metabolic alkalosis does not impair NKCC2 proton-coupled cotransport in the described manner.
Option B: Option B is incorrect: while hypoalbuminemia and braking phenomenon are real contributors, NSAID-mediated prostaglandin inhibition is not a mechanism in this patient (no NSAID use documented), and IV albumin infusion with furosemide has inconsistent trial evidence as a standard triple intervention.
Option C: Option C is incorrect: furosemide reaches the tubular lumen predominantly by active secretion (not glomerular filtration), so reduced GFR does not directly limit luminal delivery via a filtered-load mechanism; and NKCC2 downregulation is not an established mechanism of CKD-related diuretic resistance — organic acid competition at OAT transporters is the established mechanism.
Option E: Option E is incorrect: albumin-furosemide complexes are not too large for OAT1/OAT3 — the transporters actively secrete the complex; tubular fluid pH does not trap furosemide by ionization at the NKCC2 site; and NCC upregulation in the braking phenomenon occurs in the distal convoluted tubule, not NKCC2 downregulation at the thick ascending limb.

2. A 71-year-old woman with HFrEF is admitted with acute decompensation. She receives IV furosemide at 2.5 times her oral daily dose (DOSE trial-informed strategy). At 48 hours, decongestion is inadequate — JVP (jugular venous pressure) remains elevated, she has lost only 1 kg, and urine output averages 60 mL/hour. Creatinine has risen modestly from 1.1 to 1.3 mg/dL and blood pressure is stable. Which of the following best synthesizes the evidence from both the DOSE and ADVOR trials to identify the most rational next escalation step?

A) The DOSE trial established that increasing beyond 2.5 times the oral dose does not improve outcomes and continuous infusion is not superior to bolus dosing; the ADVOR trial demonstrated that adding IV acetazolamide 500 mg once daily to background loop diuretic significantly increased successful decongestion at 3 days compared to placebo; taken together, the evidence supports adding IV acetazolamide to the current furosemide regimen to achieve proximal tubule carbonic anhydrase blockade complementing the existing NKCC2 blockade — rather than further furosemide dose escalation or switching to continuous infusion
B) The DOSE trial demonstrated that continuous infusion is significantly superior to bolus dosing for decongestion at 72 hours in patients with inadequate initial response; the most rational next step is to convert from bolus furosemide to continuous IV infusion at the equivalent hourly rate, which DOSE showed produces superior decongestion specifically in patients who fail to respond to the initial bolus strategy within 48 hours
C) Both the DOSE and ADVOR trials demonstrated that diuretic resistance at 48 hours uniformly predicts failure of further pharmacological strategies; the combined evidence supports transitioning this patient to ultrafiltration (isolated ultrafiltration or continuous venovenous hemofiltration), which ADVOR demonstrated is superior to pharmacological escalation for patients with inadequate response to 2.5× oral dose furosemide at 48 hours
D) The DOSE trial established that furosemide dose can be safely escalated to 5× the oral daily dose in patients with inadequate response at 48 hours without worsening renal outcomes; the ADVOR trial supports adding acetazolamide only in patients with eGFR above 60 mL/min/1.73m², because its proximal tubule mechanism requires adequate GFR for meaningful proximal sodium delivery; since her creatinine has risen, furosemide dose escalation to 5× is the appropriate DOSE-informed strategy
E) The DOSE trial's high-dose arm showed that furosemide response at 72 hours plateaus regardless of dose, confirming that this patient has reached the natriuretic ceiling of loop diuretic therapy; the ADVOR trial's benefit with acetazolamide was limited to patients with preserved renal function (creatinine below 1.0 mg/dL at baseline), and her creatinine rise excludes her from the population in whom ADVOR benefit was demonstrated — metolazone addition for sequential nephron blockade is the only remaining pharmacological option

ANSWER: A

Rationale:

This question requires integrating the practical conclusions of two distinct trials to identify the most rational next step when standard high-dose furosemide produces inadequate decongestion. The DOSE trial demonstrated that: (1) high-dose IV furosemide (2.5× oral dose) is superior to low-dose for decongestion at 72 hours; (2) there is no significant benefit of continuous infusion over intermittent bolus dosing; and (3) further dose escalation beyond the 2.5× strategy was not tested in DOSE, so there is no established evidence that exceeding this dose improves outcomes. The ADVOR trial (2022) demonstrated that adding IV acetazolamide 500 mg once daily to standardized background IV loop diuretic therapy significantly increased successful decongestion at 3 days compared to placebo (42.2% vs. 30.5%; RR 1.46; p<0.001). Acetazolamide's mechanism is complementary: carbonic anhydrase inhibition in the proximal tubule reduces bicarbonate-coupled sodium reabsorption, delivering additional sodium to the loop of Henle on top of the sodium that furosemide's NKCC2 blockade already failed to reclaim — a proximal site of action that adds natriuretic effect without simply escalating the loop diuretic dose. Taken together, the evidence favors adding acetazolamide (ADVOR) rather than escalating furosemide beyond the DOSE-established strategy or switching to continuous infusion (not superior per DOSE).

Option B: Option B is incorrect: DOSE did not demonstrate that continuous infusion is superior to bolus dosing overall or specifically in patients with inadequate initial response; the trial found no significant difference between infusion strategies.
Option C: Option C is incorrect: ADVOR did not compare acetazolamide to ultrafiltration, and neither DOSE nor ADVOR established ultrafiltration as the indicated next step after 48-hour pharmacological inadequacy; the CARRESS-HF trial actually found ultrafiltration was not superior to pharmacological therapy for decongestion in acute HF.
Option D: Option D is incorrect: DOSE did not establish a 5× oral dose escalation pathway, and ADVOR did not restrict its benefit to patients with eGFR above 60 mL/min/1.73m²; the modest creatinine rise in this patient does not exclude her from ADVOR-type benefit.
Option E: Option E is incorrect: DOSE did not show a natriuretic ceiling confirming invariable plateau at any dose, and ADVOR did not limit its benefit to patients with baseline creatinine below 1.0 mg/dL; this creatinine restriction is a fabricated exclusion criterion.

3. A 68-year-old man with HFrEF is receiving IV furosemide 120 mg twice daily, metolazone 5 mg daily, and spironolactone 25 mg daily. After 30 hours of this regimen, labs return: K⁺ 2.9 mEq/L, Mg 1.1 mg/dL, Na 131 mEq/L, creatinine 1.9 mg/dL (up from 1.3 mg/dL). His blood pressure is 98/60 mmHg and he is producing 350 mL/hour of urine. Which of the following best explains why his hypokalemia is resistant to potassium replacement alone, and identifies the correct priority sequence of interventions?

A) The K⁺ of 2.9 mEq/L is driven primarily by spironolactone's paradoxical potassium-wasting effect at doses below 50 mg daily; at 25 mg, spironolactone incompletely blocks the mineralocorticoid receptor, leaving partial aldosterone-driven Na-K exchange intact while simultaneously reducing the aldosterone-mediated potassium-retaining signal in the proximal tubule; the correct intervention is to double spironolactone to 50 mg daily to achieve complete MR blockade and reverse the potassium wasting
B) The hypokalemia reflects transcellular potassium shift from extracellular to intracellular compartments driven by the metabolic alkalosis produced by aggressive diuresis; the low Mg and Na are secondary to the alkalosis-driven shifts; IV potassium replacement will be ineffective until sodium bicarbonate is administered to correct the alkalosis and reverse the transcellular shift, after which potassium will redistribute extracellularly without further replacement
C) Hypomagnesemia (Mg 1.1 mg/dL) perpetuates the hypokalemia by impairing Na-K-ATPase activity in the renal tubule, reducing intracellular potassium in principal cells and thereby increasing the electrochemical gradient for ROMK-mediated potassium secretion into the tubular lumen; potassium replacement will be ineffective and the hypokalemia will recur until magnesium is repleted first; the correct priority sequence is: (1) hold metolazone immediately given the hemodynamic instability and electrolyte crisis; (2) replete magnesium IV; (3) replete potassium IV; (4) reassess diuretic strategy when hemodynamically stable
D) The hypokalemia is caused by furosemide-induced upregulation of the H-K-ATPase in intercalated cells of the collecting duct; aggressive loop diuresis stimulates proton secretion in exchange for potassium reabsorption, and the net effect is potassium trapping inside intercalated cells in a form that is not detected by serum potassium measurement; IV potassium fails to raise serum potassium because it is immediately sequestered by the overactive H-K-ATPase
E) The hypokalemia and hypomagnesemia are both caused by spironolactone blocking the magnesium-retaining function of the mineralocorticoid receptor in the distal nephron; at doses above 12.5 mg daily, spironolactone's MR blockade eliminates a protective aldosterone-magnesium cotransport mechanism in the collecting duct, and both electrolyte deficits resolve only after spironolactone is discontinued and aldosterone-driven magnesium cotransport is restored

ANSWER: C

Rationale:

This patient has a life-threatening electrolyte emergency from combined sequential nephron blockade and MRA therapy. The critical pathophysiological insight is that hypomagnesemia perpetuates hypokalemia through a well-established renal mechanism: magnesium is required for normal Na-K-ATPase function in the basolateral membrane of renal tubular principal cells; when intracellular magnesium falls, Na-K-ATPase activity is impaired, reducing the intracellular potassium concentration in principal cells; the reduced intracellular potassium increases the electrochemical driving force for ROMK-mediated potassium secretion from the cell into the tubular lumen, producing ongoing urinary potassium wasting even in the presence of systemic hypokalemia. The clinical consequence is that IV potassium supplementation is rapidly excreted in the urine as fast as it is administered, and hypokalemia cannot be corrected until magnesium is repleted first. This is a bedside rule of critical importance: refractory hypokalemia always demands magnesium measurement and repletion before or concurrent with potassium replacement. The priority sequence in this hemodynamically unstable patient is: (1) hold metolazone immediately — the hemodynamic deterioration (BP 98/60 mmHg), dramatic urine output (350 mL/hour), and electrolyte crisis indicate excessive diuresis requiring urgent de-escalation; (2) replete IV magnesium; (3) replete IV potassium; (4) reassess the diuretic regimen once stabilized. Spironolactone should be held given the volume depletion, not escalated.

Option A: Option A is incorrect: spironolactone at 25 mg does not have a paradoxical potassium-wasting effect; at any therapeutic dose it reduces potassium excretion by blocking MR — the hypokalemia here is driven by the loop diuretic and metolazone combination overwhelming spironolactone's protective effect; doubling spironolactone in a hemodynamically compromised patient would worsen the situation.
Option B: Option B is incorrect: while metabolic alkalosis does produce some transcellular potassium shift intracellularly, the magnitude of the K⁺ 2.9 mEq/L depletion in this context is primarily driven by renal losses, not transcellular shift; sodium bicarbonate administration would worsen the alkalosis and is not the correct intervention.
Option D: Option D is incorrect: furosemide does not upregulate H-K-ATPase to cause intracellular potassium trapping; H-K-ATPase in intercalated cells secretes protons and reabsorbs potassium, but its upregulation would cause potassium retention rather than potassium wasting; this mechanism is fabricated.
Option E: Option E is incorrect: spironolactone does not block a magnesium-retaining function of the mineralocorticoid receptor through an aldosterone-magnesium cotransport mechanism; no such cotransport mechanism exists; and discontinuing spironolactone removes a potassium-sparing benefit without providing any mechanistic basis for magnesium retention.

4. A 64-year-old man with HFrEF had an anterior MI (myocardial infarction) 8 months ago (LVEF 33%, NYHA class II) and was started on eplerenone 25 mg daily at day 10 post-MI, now titrated to 50 mg daily. He asks his cardiologist: "Which study proved that this drug helps me?" The cardiologist explains that three major trials (RALES, EMPHASIS-HF, EPHESUS) are relevant but that one most directly supports his current treatment. Which of the following correctly identifies which trial most directly supports this patient's MRA prescription and explains why the other two, while relevant background, are less directly applicable?

A) RALES most directly supports his prescription: RALES is the only trial that demonstrated all-cause mortality reduction with an MRA in HFrEF with LVEF below 35%, and his LVEF of 33% places him squarely within the RALES enrollment criteria; EMPHASIS-HF and EPHESUS used eplerenone rather than spironolactone and are not directly applicable because eplerenone and spironolactone cannot be assumed to have identical outcomes data across all HFrEF subgroups
B) EPHESUS most directly supports his prescription: he received eplerenone initiated at day 10 post-MI for LVEF 40% or less with symptomatic HF — precisely the EPHESUS enrollment criteria (acute MI complicated by LV dysfunction and either symptomatic HF or diabetes, initiated 3–14 days post-MI on background ACE inhibitor and beta-blocker); RALES enrolled NYHA class III–IV on older GDMT without routine beta-blocker use and studied spironolactone rather than eplerenone; EMPHASIS-HF enrolled chronic stable HFrEF, not the acute post-MI setting that defined his initiation
C) EMPHASIS-HF most directly supports his prescription: he is now 8 months post-MI with NYHA class II symptoms on modern GDMT, which is the exact population EMPHASIS-HF enrolled; EPHESUS was relevant at initiation (day 10 post-MI) but its evidence applies only to the first 12 months after MI, after which the EMPHASIS-HF population definition replaces it as the applicable trial; RALES does not apply because it enrolled only NYHA class III–IV patients
D) All three trials apply equally to this patient and no single trial is most directly applicable; AHA/ACC/HFSA guidelines do not distinguish between post-MI and non-post-MI HFrEF for the MRA class I recommendation, and the combined evidence from RALES, EPHESUS, and EMPHASIS-HF collectively supports a class I recommendation that is indifferent to the specific clinical pathway by which a patient developed HFrEF
E) Neither RALES nor EMPHASIS-HF directly supports his prescription because both studied stable chronic HFrEF; EPHESUS provides the only applicable evidence but only for the first 30 days post-MI; after 30 days, no randomized trial evidence supports continuing eplerenone in a post-MI HFrEF patient with NYHA class II symptoms, and continuation beyond 30 days is based on extrapolation rather than direct trial evidence

ANSWER: B

Rationale:

This question tests the ability to match a specific patient scenario to the most directly applicable trial from among three landmark MRA studies, recognizing that trials have distinct population definitions that determine their direct applicability. This patient's eplerenone was initiated at day 10 post-MI for LVEF 33% (at or below 40%) with symptomatic heart failure — this is the precise EPHESUS enrollment scenario. EPHESUS enrolled 6,632 patients with acute MI complicated by LV dysfunction (LVEF 40% or less) and either symptomatic HF or diabetes, randomized 3–14 days post-MI on background ACE inhibitor and beta-blocker to eplerenone 25 mg daily (titrated to 50 mg). The initiation decision for this patient was EPHESUS-driven. RALES is less directly applicable for two reasons: it studied spironolactone (not eplerenone), and it enrolled NYHA class III–IV patients on older GDMT without routine beta-blocker use — a substantially different population and treatment context. EMPHASIS-HF studied chronic stable HFrEF (not post-MI acute initiation) with NYHA class II on modern GDMT — relevant background evidence but not the study that supported his initiation decision. At 8 months post-MI, the EPHESUS evidence that justified initiation continues to justify continuation; there is no trial-defined time boundary at which EPHESUS evidence "expires" and EMPHASIS-HF takes over — both reinforce the clinical rationale for ongoing MRA therapy in his situation.

Option A: Option A is incorrect: RALES enrolled NYHA class III–IV with spironolactone on older GDMT — it does not most directly support this patient's eplerenone prescription in the post-MI setting; the LVEF overlap does not make RALES the primary applicable trial when EPHESUS directly addressed the post-MI initiation scenario.
Option C: Option C is incorrect: while EMPHASIS-HF is now highly relevant to his current clinical profile, the trial that most directly supported his original prescription (and by extension its continuation) was EPHESUS — the post-MI initiation context is what EPHESUS specifically studied, and there is no 12-month EPHESUS validity expiration after which EMPHASIS-HF replaces it.
Option D: Option D is incorrect: while guidelines do give a class I recommendation across the HFrEF population, the question asks which trial most directly supports this patient — the answer requires distinguishing the post-MI initiation population (EPHESUS) from the chronic stable HFrEF population (RALES, EMPHASIS-HF).
Option E: Option E is incorrect: EPHESUS evidence does not expire at 30 days post-MI; the trial tracked outcomes over approximately 16 months of follow-up, and its benefit extended well beyond the first month; continuation of eplerenone is fully evidence-supported beyond 30 days.

5. A 67-year-old man with HFrEF (LVEF 36%) was started on eplerenone 25 mg daily at day 7 post-STEMI per EPHESUS criteria and titrated to 50 mg daily at 4 weeks. He is also on ramipril 10 mg daily and metoprolol succinate 50 mg daily. At week 6, a renal duplex ultrasound ordered for newly identified hypertension reveals bilateral renal artery stenosis (RAS) with greater than 60% stenosis bilaterally. His current potassium is 4.9 mEq/L and creatinine is 1.4 mg/dL (eGFR 52 mL/min/1.73m²). Which of the following best describes the pharmacological reasoning for reassessing his current GDMT regimen in light of this finding?

A) Bilateral RAS is a contraindication to eplerenone but not to ramipril; eplerenone's MR blockade in the collecting duct reduces sodium reabsorption and thereby lowers the effective circulating volume, which triggers compensatory renin release from the stenotic kidneys; this renin surge overwhelms the MR blockade and paradoxically increases aldosterone levels to supranormal concentrations, producing the dangerous aldosterone escape phenomenon that is specific to MRA therapy in bilateral RAS
B) Bilateral RAS requires discontinuation of eplerenone but not ramipril; eplerenone's mechanism in bilateral RAS specifically reduces the efferent arteriolar vasodilation that aldosterone normally provides through a non-genomic pathway in the glomerular mesangium, removing a compensatory filtration mechanism that is uniquely important in bilateral RAS and producing a selective eplerenone-specific GFR collapse not shared by ACE inhibitors
C) Neither ramipril nor eplerenone need be modified; bilateral RAS increases aldosterone-driven sodium retention and the combined RAAS blockade of ramipril and eplerenone is particularly beneficial in this setting because it simultaneously reduces blood pressure through ACE inhibition and blocks the adverse fibrotic effects of excess aldosterone on the kidneys, providing a dual nephroprotective effect that outweighs the hemodynamic risk
D) Bilateral RAS makes all RAAS blockade hazardous because both kidneys depend on angiotensin II-mediated efferent arteriolar constriction to maintain intraglomerular pressure and GFR; ramipril already reduces angiotensin II-driven efferent tone, and eplerenone's additional reduction in effective circulating volume (through MR blockade and reduced sodium retention) further compromises the perfusion pressure that sustains GFR across the stenotic renal arteries; the combination substantially increases the risk of acute renal failure, warranting reassessment of whether both agents can be safely continued and close monitoring of renal function and potassium
E) Bilateral RAS requires reconsideration of the full RAAS-blocking regimen: in bilateral RAS, both kidneys depend on angiotensin II-mediated efferent arteriolar vasoconstriction to maintain intraglomerular pressure across the fixed stenotic resistance; ramipril reduces angiotensin II-driven efferent tone; eplerenone reduces effective circulating volume through sodium and water retention blockade; together they remove two compensatory mechanisms for GFR maintenance, substantially increasing the risk of acute kidney injury; in a post-MI patient with a compelling EPHESUS-supported indication for eplerenone, the appropriate response is neither automatic discontinuation nor continuation without monitoring — it is close surveillance of creatinine and potassium, shared decision-making about the balance between renal risk and survival benefit, and consideration of nephrology input for RAS management options including revascularization

ANSWER: E

Rationale:

Bilateral renal artery stenosis creates a hemodynamic vulnerability that makes any RAAS blockade potentially hazardous. In bilateral RAS, both kidneys are perfused at reduced arterial pressure distal to the stenoses; to maintain GFR across this reduced perfusion pressure, both kidneys rely on angiotensin II-mediated constriction of the efferent arteriole, which raises intraglomerular hydrostatic pressure and maintains filtration despite the reduced afferent input. Ramipril's ACE inhibition reduces angiotensin II, reducing efferent arteriolar tone and lowering intraglomerular pressure — a risk of acute kidney injury well recognized in bilateral RAS. Eplerenone adds a second mechanism of risk: by blocking aldosterone-driven sodium reabsorption in the collecting duct, it reduces effective circulating volume, further lowering renal perfusion pressure to the already pressure-compromised kidneys. The combination of reduced efferent arteriolar tone (from ACE inhibitor) and reduced perfusion pressure (from MRA-induced volume reduction) is more hazardous than either alone in bilateral RAS. However, this patient has a compelling, survival-proven EPHESUS indication for eplerenone — abrupt discontinuation of a post-MI MRA would remove a class I survival benefit. The appropriate response is not automatic discontinuation or unchanged continuation, but rather careful reassessment: close creatinine and potassium monitoring, shared decision-making weighing renal risk against survival benefit, and consideration of whether renal revascularization (angioplasty or stenting) could reduce the RAS hemodynamic risk and allow safer GDMT continuation. Option D is correct in its pharmacological reasoning but incomplete in its clinical conclusion — it describes the mechanism accurately but stops at "warranting reassessment" without defining the nuanced approach that preserves a survival benefit where possible; Option E provides the full, clinically complete answer.

Option A: Option A is incorrect: bilateral RAS is not a contraindication specifically to eplerenone while sparing ACE inhibitors — both drug classes carry hemodynamic risk in bilateral RAS; the "aldosterone escape phenomenon" described is not a recognized mechanism of MRA-specific hazard in bilateral RAS.
Option B: Option B is incorrect: eplerenone does not reduce aldosterone-mediated efferent arteriolar vasodilation through a non-genomic glomerular mesangium pathway; this is a fabricated mechanism; and ACE inhibitors share the hemodynamic hazard in bilateral RAS.
Option C: Option C is incorrect: bilateral RAS makes RAAS blockade hazardous, not particularly beneficial; claiming dual nephroprotection that outweighs hemodynamic risk in bilateral RAS is contrary to established nephrology and cardiology guidance.

6. A clinical pharmacologist is reviewing the TOPCAT trial with trainees and presents the following data: the overall primary endpoint (cardiovascular death, aborted cardiac arrest, or HF hospitalization) was not significant (HR 0.89; p=0.14); patients from Russia and Georgia had dramatically lower event rates than patients from the Americas; and post-hoc pharmacokinetic analysis found that plasma canrenone concentrations — a spironolactone metabolite serving as an adherence biomarker — were near zero in the Russia/Georgia cohort. A trainee asks: "Does this mean the overall result is meaningless?" Which of the following best evaluates the methodological implications and the appropriate clinical interpretation?

A) The trainee is correct: the near-zero canrenone levels in Russia and Georgia confirm that the overall TOPCAT result is invalid and should be disregarded entirely; the FDA has acknowledged this and retroactively reclassified spironolactone as a class I recommendation for all HFpEF based on the Americas-only data, which represents the only pharmacologically valid trial population
B) The near-zero canrenone levels indicate that all TOPCAT patients were non-adherent because canrenone is a renally-eliminated metabolite whose plasma concentration falls to zero whenever GFR falls below 45 mL/min/1.73m²; since most HFpEF patients have CKD, the near-zero canrenone levels simply reflect the CKD prevalence in the trial and have no bearing on drug adherence in either geographic cohort
C) The canrenone finding strengthens the overall TOPCAT result: when patients who did not adhere to study medication are included in an intention-to-treat analysis, the benefit of spironolactone is diluted but not eliminated; the fact that the HR was 0.89 with a non-adherent subgroup included confirms that the true treatment effect is a 30% reduction in events (corrected for non-adherence dilution), matching the RALES mortality result and supporting a class I recommendation
D) The canrenone biomarker finding raises a serious but unresolved question of trial validity: near-zero metabolite concentrations in an entire geographic cohort suggest those patients may not have received active drug, which would dilute the observed treatment effect in the overall intention-to-treat analysis; the Americas subgroup analyses showing benefit provide a signal that is scientifically plausible given the pharmacokinetic evidence, but post-hoc subgroup analyses cannot replace a pre-specified primary endpoint; the appropriate clinical interpretation is that the evidence for spironolactone in HFpEF remains genuinely uncertain, justifying a class IIb rather than class I recommendation
E) The canrenone finding is irrelevant to the clinical interpretation because TOPCAT used an intention-to-treat analysis, which by definition attributes the outcomes to assigned treatment regardless of adherence; the appropriate statistical interpretation of an intention-to-treat analysis requires accepting the primary endpoint result (HR 0.89; p=0.14) as the definitive measure of spironolactone's effect in HFpEF, and any post-hoc subgroup or pharmacokinetic analysis is hypothesis-generating only and cannot modify the class of recommendation

ANSWER: D

Rationale:

This question tests critical appraisal of a methodologically complex trial where post-hoc pharmacokinetic data raise genuine questions about whether the randomized intervention was actually administered in a major portion of the trial population. The canrenone biomarker finding is scientifically important and cannot simply be dismissed: if patients in Russia and Georgia did not receive active spironolactone — whether due to dispensing error, counterfeit drug, or systematic non-administration — then the TOPCAT comparison in those regions was not spironolactone versus placebo but rather placebo versus placebo. Including a large placebo-versus-placebo comparison in an intention-to-treat analysis would dilute the true treatment effect of spironolactone to null, producing exactly the non-significant overall result (HR 0.89; p=0.14) even if spironolactone has real efficacy in the Americas population. The Americas subgroup showing significant HF hospitalization reduction is pharmacologically plausible given confirmed drug exposure, but post-hoc subgroup analyses — even with compelling pharmacokinetic support — are hypothesis-generating, not confirmatory. The intellectually honest position is uncertainty: the evidence is neither strong enough for a class I recommendation nor definitively negative. AHA/ACC/HFSA 2022 guidelines appropriately assigned a class IIb recommendation, reflecting plausible but unproven benefit.

Option A: Option A is incorrect: the FDA has not reclassified spironolactone as class I in HFpEF based on TOPCAT Americas data; the class IIb recommendation reflects the residual uncertainty.
Option B: Option B is incorrect: canrenone is not cleared exclusively at eGFR above 45 mL/min/1.73m²; its renal elimination does not produce zero plasma concentrations in all CKD patients; the near-zero levels were geographically concentrated in Russia and Georgia specifically, not uniformly distributed across the CKD subgroup.
Option C: Option C is incorrect: applying a non-adherence correction factor to derive a 30% event reduction from an HR of 0.89 is a statistical extrapolation that was not pre-specified; and RALES studied a fundamentally different population (HFrEF NYHA III–IV, not HFpEF) — the comparison is not valid for deriving a true effect estimate in HFpEF.
Option E: Option E is incorrect: while intention-to-treat analysis is methodologically appropriate for regulatory and efficacy purposes, it specifically assumes that randomization was properly executed and that patients received their assigned treatment at least partially; when post-hoc pharmacokinetic data raise serious questions about whether randomized treatment was actually administered, the intention-to-treat principle does not prevent scientific consideration of those data — ignoring the canrenone finding on methodological grounds would be an oversimplification that obscures the genuine uncertainty.

7. At a case conference, a cardiologist states: "I always discharge my HF patients on torsemide instead of furosemide because TRANSFORM-HF proved it reduces mortality." A second cardiologist challenges this. Which of the following best evaluates the accuracy of the first cardiologist's claim and identifies what TRANSFORM-HF actually demonstrated?

A) The first cardiologist's claim is inaccurate: TRANSFORM-HF found no significant difference in all-cause mortality between torsemide and furosemide (HR 1.02; p=0.82) and no significant difference in the composite of mortality and hospitalization (HR 0.92; p=0.26); the preference for torsemide is pharmacokinetically — not mortality-outcome — justified, based on its higher and more consistent oral bioavailability (approximately 80–90% versus furosemide's variable 10–100%) and longer duration of action, which reduce day-to-day variability in diuretic effect rather than reducing mortality
B) The first cardiologist's claim is accurate: TRANSFORM-HF demonstrated a significant reduction in 60-day HF-specific rehospitalization with torsemide (HR 0.81; p=0.03), and while the all-cause mortality endpoint was not significant, the ACC/AHA HF guidelines interpret significant reduction in HF rehospitalization as a mortality-equivalent outcome for the purpose of drug class recommendations — which is the basis for the class I torsemide recommendation over furosemide
C) The first cardiologist's claim is partially correct: TRANSFORM-HF demonstrated significant mortality reduction specifically in the subgroup with eGFR above 60 mL/min/1.73m² (HR 0.74; p=0.04) but not in the overall population; since most HF patients discharged from hospital have reasonably preserved renal function, the first cardiologist's practice is evidence-based for the majority of their patients even though the overall trial result was neutral
D) The first cardiologist's claim reflects a common misinterpretation: TRANSFORM-HF was a non-inferiority trial that established torsemide as non-inferior to furosemide for all-cause mortality; non-inferiority trials by design cannot demonstrate superiority, so stating that torsemide "reduces mortality" violates the trial's statistical framework; the correct statement is that torsemide does not increase mortality compared to furosemide, which supports its use as a safe alternative but not as a mortality-reducing intervention
E) The first cardiologist's claim is accurate for the pre-specified subgroup of patients discharged after first HF hospitalization: TRANSFORM-HF demonstrated a significant all-cause mortality reduction in first-hospitalization patients (HR 0.77; p=0.01), and since most clinical discharge decisions involve patients being hospitalized for the first time, the generalization to routine discharge practice is evidence-appropriate even if the overall trial was neutral

ANSWER: A

Rationale:

TRANSFORM-HF (Mentz et al., JAMA, 2023) enrolled 2,859 patients hospitalized with heart failure and randomized them to torsemide versus furosemide as maintenance oral loop diuretic therapy. The primary endpoint of all-cause mortality showed no significant difference (HR 1.02; 95% CI 0.89–1.18; p=0.82). The key secondary composite of all-cause mortality or all-cause hospitalization was also not significantly different (HR 0.92; 95% CI 0.83–1.02; p=0.26). The first cardiologist's claim that TRANSFORM-HF "proved" torsemide reduces mortality is therefore factually incorrect — the trial demonstrated equivalence in mortality, not superiority of torsemide. The rational basis for preferring torsemide is pharmacokinetic: torsemide's approximately 80–90% oral bioavailability (consistent across patients and clinical states, including volume-overloaded states with gut edema) versus furosemide's highly variable 10–100% (average ~50%) means that torsemide produces more predictable plasma concentrations and more consistent diuretic responses per oral dose — a pharmacokinetic argument for reliability, not a mortality argument. Some secondary analyses in TRANSFORM-HF suggested fewer diuretic-related side effects with torsemide and possible quality-of-life advantages. The second cardiologist's challenge is justified, and clinical practice should be informed by what the trial actually showed rather than what clinicians wish it had shown.

Option B: Option B is incorrect: TRANSFORM-HF did not demonstrate a significant reduction in HF rehospitalization with torsemide (HR 0.92 for the composite was non-significant), and guideline frameworks do not classify non-significant rehospitalization trends as mortality-equivalent outcomes justifying class I recommendations.
Option C: Option C is incorrect: the eGFR above 60 mL/min/1.73m² mortality subgroup benefit described is fabricated — no such pre-specified or post-hoc subgroup showing HR 0.74 appears in the published TRANSFORM-HF results.
Option D: Option D is incorrect: TRANSFORM-HF was a superiority trial (not a non-inferiority trial); the primary analysis tested whether torsemide was superior to furosemide for all-cause mortality, and the result was a null finding.
Option E: Option E is incorrect: the first-hospitalization mortality subgroup result described (HR 0.77; p=0.01) is fabricated — no such subgroup analysis appears in the published TRANSFORM-HF primary results.

8. A 62-year-old woman with HFrEF (LVEF 30%, NYHA class II) is on optimized GDMT including sacubitril/valsartan, carvedilol, and spironolactone 25 mg daily. Her cardiologist adds empagliflozin 10 mg daily (an SGLT2 inhibitor). Her potassium before empagliflozin addition was 4.8 mEq/L. Which of the following best explains whether the addition of empagliflozin is expected to increase, decrease, or have a neutral effect on her serum potassium, and the mechanism responsible?

A) Empagliflozin will significantly increase her potassium because SGLT2 (sodium-glucose cotransporter 2) inhibition in the proximal tubule diverts sodium from the SGLT2 pathway to the NHE3 (sodium-hydrogen exchanger 3) pathway, increasing proximal tubule bicarbonate-coupled sodium reabsorption, which reduces distal sodium delivery and thereby reduces the electrochemical gradient for collecting duct potassium secretion — producing clinically significant potassium retention that compounds the spironolactone effect
B) Empagliflozin will have no effect on her serum potassium because SGLT2 inhibitors act exclusively in the proximal tubule on glucose transport and have no downstream effects on potassium handling in any nephron segment; potassium transport in the collecting duct is regulated entirely by aldosterone and distal sodium delivery, neither of which is affected by SGLT2 blockade
C) Empagliflozin is expected to have a modestly potassium-lowering or potassium-neutral effect in this patient: SGLT2 inhibition increases distal sodium delivery by reducing proximal glucose-coupled sodium reabsorption, which mildly increases collecting duct Na-K exchange and potassium excretion; clinical trial data from EMPEROR-Reduced and DAPA-HF demonstrate that SGLT2 inhibitors are associated with lower rates of hyperkalemia compared to placebo in HFrEF patients, including those on MRA therapy — suggesting that empagliflozin may partially offset spironolactone's potassium-retaining effect and could potentially enable MRA therapy continuation in patients with borderline potassium
D) Empagliflozin will cause severe hyperkalemia because its osmotic diuresis effect produces significant volume contraction, activating the renin-angiotensin-aldosterone system; in a patient already on spironolactone (which blocks aldosterone-driven potassium excretion), the aldosterone surge from SGLT2 inhibitor-induced volume contraction cannot increase collecting duct potassium excretion, leaving the patient with both a potassium-retaining aldosterone surge and blocked MR — producing uncontrolled potassium accumulation
E) Empagliflozin will moderately increase her potassium because SGLT2 inhibitors block the proximal tubule Na-K-ATPase as an off-target effect, reducing intracellular potassium uptake in proximal tubule cells and raising luminal potassium concentrations; this luminal potassium accumulation drives passive back-diffusion of potassium into peritubular capillaries, increasing serum potassium in proportion to the degree of SGLT2 inhibition achieved

ANSWER: C

Rationale:

SGLT2 inhibitors and mineralocorticoid receptor antagonists have distinct and partially offsetting effects on potassium handling, a pharmacodynamically important interaction in the contemporary HFrEF patient on quadruple GDMT. SGLT2 inhibitors block glucose-coupled sodium reabsorption in the proximal convoluted tubule; this reduces proximal sodium reabsorption and increases the sodium load delivered to more distal nephron segments, including the cortical collecting duct. The increased distal sodium delivery mildly augments Na-K exchange in principal cells, increasing urinary potassium excretion. This mechanism is the pharmacological basis for the observed potassium-lowering or potassium-neutral effect of SGLT2 inhibitors in clinical trials. In both EMPEROR-Reduced (empagliflozin in HFrEF) and DAPA-HF (dapagliflozin in HFrEF), patients receiving SGLT2 inhibitors had significantly lower rates of hyperkalemia compared to placebo — including in the subgroup receiving concomitant MRA therapy. This finding has generated substantial clinical interest in SGLT2 inhibitors as agents that may enable MRA continuation or initiation in patients with borderline-elevated potassium, by counteracting the potassium-retaining effect of MRAs. For this patient with a potassium of 4.8 mEq/L on spironolactone, empagliflozin addition is expected to be potassium-neutral or to reduce potassium modestly — a clinically favorable interaction.

Option A: Option A is incorrect: SGLT2 inhibition does not divert sodium to NHE3 in a way that increases bicarbonate-coupled sodium reabsorption and reduces distal delivery; SGLT2 blockade reduces proximal sodium reabsorption overall, increasing rather than decreasing distal delivery — the opposite of what Option A describes.
Option B: Option B is incorrect: SGLT2 inhibitors do have downstream effects on potassium handling through increased distal sodium delivery; clinical trial data confirm their potassium-lowering effect in HFrEF, contradicting the claim of no potassium effect.
Option D: Option D is incorrect: while SGLT2 inhibitors do produce some osmotic diuresis and modest RAAS activation, the clinical net effect observed in large HFrEF trials is potassium reduction (not increase), and the described mechanism of blocked MR combined with aldosterone surge causing uncontrolled potassium accumulation is not supported by clinical evidence.
Option E: Option E is incorrect: SGLT2 inhibitors do not block the proximal tubule Na-K-ATPase as an off-target mechanism; this is a fabricated pharmacological action with no basis in SGLT2 inhibitor pharmacology.

9. A 76-year-old woman with HFrEF (LVEF 28%) presents with worsening edema resistant to furosemide 80 mg twice daily. She has been on furosemide for 20 months. Her eGFR is 29 mL/min/1.73m², albumin is normal, and cardiac output is clinically adequate. Medication review reveals she started celecoxib 200 mg daily for knee pain 5 weeks ago. Her JVP is elevated and she has 3+ pitting edema. Which of the following best identifies all active resistance mechanisms and the correct priority sequence for addressing them?

A) Three mechanisms are active — braking phenomenon, CKD organic acid competition, and celecoxib-mediated COX-2 inhibition; the correct priority sequence is: (1) add metolazone for sequential nephron blockade to overcome braking phenomenon; (2) increase furosemide to 160 mg twice daily to compensate for organic acid competition; (3) counsel the patient to take celecoxib with food to reduce renal prostaglandin inhibition
B) Two mechanisms are active — braking phenomenon and celecoxib-mediated prostaglandin inhibition; CKD at eGFR 29 mL/min/1.73m² does not contribute meaningful organic acid competition until eGFR falls below 20 mL/min/1.73m²; the correct priority sequence is: (1) discontinue celecoxib; (2) reassess diuretic response at 1–2 weeks; (3) add metolazone only if resistance persists after NSAID discontinuation
C) Two mechanisms are active — CKD organic acid competition and braking phenomenon; celecoxib as a selective COX-2 inhibitor does not affect renal prostaglandin synthesis because renal prostaglandins are produced exclusively by COX-1, not COX-2; the correct sequence is to add metolazone immediately and escalate furosemide simultaneously to compensate for organic acid transporter competition
D) Three mechanisms are active: celecoxib-mediated COX-2 inhibition reducing renal prostaglandin-driven vasodilation and furosemide tubular delivery; CKD at eGFR 29 mL/min/1.73m² causing uremic organic acid accumulation that competes with furosemide for OAT1/OAT3 transport; and the braking phenomenon from 20 months of furosemide causing NCC upregulation in the distal convoluted tubule; the correct priority sequence is: (1) discontinue celecoxib immediately and substitute acetaminophen — the only intervention that is immediate, costless, and removes a formally contraindicated drug; (2) reassess diuretic response at 1–2 weeks after NSAID removal; (3) if resistance persists, add metolazone for sequential nephron blockade to address the braking phenomenon
E) Four mechanisms are active — celecoxib COX-2 inhibition, CKD organic acid competition, braking phenomenon, and spironolactone-mediated paradoxical potassium wasting impairing the NKCC2 driving gradient; all four must be addressed simultaneously: discontinue celecoxib, switch furosemide to torsemide to bypass organic acid competition, add metolazone, and double spironolactone dose — a four-drug simultaneous intervention is required to overcome the convergent resistance

ANSWER: D

Rationale:

This patient has three simultaneous, well-established mechanisms of diuretic resistance that must be identified and addressed in the correct priority order. First, celecoxib-mediated COX-2 inhibition: renal prostaglandin synthesis in the kidney involves both COX-1 and COX-2 isoforms; celecoxib's selective COX-2 inhibition reduces renal prostaglandin E2 production, impairing the prostaglandin-mediated vasodilation that normally maintains renal blood flow in the neurohormonal-activated HFrEF patient, reduces furosemide delivery to OAT1/OAT3 secretion sites, and blunts furosemide's early venodilatory hemodynamic effect. NSAIDs — including selective COX-2 inhibitors — are formally contraindicated in HFrEF. Second, CKD organic acid competition: eGFR of 29 mL/min/1.73m² is in the severe CKD range (stage 4 boundary) where uremic solute accumulation is clinically meaningful; retained organic acids (hippurate, indoxyl sulfate) compete with furosemide for OAT1/OAT3 transport, reducing luminal furosemide concentrations. Third, braking phenomenon: 20 months of furosemide has produced distal convoluted tubule NCC upregulation, increasing distal sodium reclamation and attenuating net natriuresis. The priority sequence reflects risk-benefit logic: (1) remove celecoxib first — this is costless, immediate, removes a contraindicated drug, and may substantially restore furosemide response within days; (2) reassess after NSAID removal before escalating diuretics — the response may be sufficient; (3) add metolazone for sequential nephron blockade if needed after removing the reversible NSAID component.

Option A: Option A is incorrect: celecoxib does affect renal prostaglandin synthesis (COX-2 is active in the kidney), and taking celecoxib with food does not mitigate renal prostaglandin inhibition — discontinuation is required.
Option B: Option B is incorrect: organic acid competition at eGFR 29 mL/min/1.73m² is clinically significant; the 20 mL/min/1.73m² threshold described is a fabricated cutoff — organic acid accumulation is meaningful at eGFR below approximately 30 mL/min/1.73m².
Option C: Option C is incorrect: COX-2 is expressed in the kidney and contributes to renal prostaglandin synthesis; selective COX-2 inhibitors do impair renal prostaglandin production and can cause diuretic resistance and fluid retention — the claim that renal prostaglandins are exclusively COX-1-derived is inaccurate.
Option E: Option E is incorrect: there is no fourth mechanism of spironolactone-mediated potassium wasting impairing the NKCC2 driving gradient — this mechanism is fabricated; and a four-drug simultaneous intervention without stepwise assessment is pharmacologically irrational and carries high electrolyte and hemodynamic risk.

10. A 70-year-old man with post-MI HFrEF (LVEF 34%, 6 months post-STEMI, NYHA class II) is on eplerenone 50 mg daily, lisinopril 10 mg daily, carvedilol 25 mg twice daily, and empagliflozin 10 mg daily. His eGFR is 38 mL/min/1.73m² and his potassium is 5.4 mEq/L on two consecutive measurements taken 1 week apart. He has no dietary potassium excess, is not on trimethoprim or NSAIDs, and the specimens were processed promptly. His cardiologist wants to avoid discontinuing eplerenone given its EPHESUS-supported survival benefit. Which of the following best represents the most appropriate strategy to manage his hyperkalemia while preserving eplerenone therapy?

A) Eplerenone must be permanently discontinued: a confirmed potassium of 5.4 mEq/L on two consecutive measurements in a patient with eGFR 38 mL/min/1.73m² represents an absolute pharmacological contraindication to MRA therapy; the EPHESUS survival benefit cannot be safely preserved once documented CKD-stage-3b hyperkalemia occurs on dual RAAS blockade, and the risk of life-threatening arrhythmia from any further potassium rise outweighs the survival benefit
B) Reduce eplerenone to 25 mg daily and initiate patiromer (a potassium binder) or SZC (sodium zirconium cyclosilicate) with the explicit goal of re-titrating eplerenone back to 50 mg once potassium is controlled below 5.0 mEq/L; clinical trial evidence from the AMBER trial demonstrates that potassium binders enable MRA continuation in patients with CKD and hyperkalemia who would otherwise require dose reduction or discontinuation — preserving the GDMT indication while managing the electrolyte risk
C) Discontinue lisinopril and replace it with hydralazine-isosorbide dinitrate; eplerenone should continue at 50 mg daily because the ACE inhibitor is the dominant hyperkalemia driver in this combination, and its removal will lower potassium to the target range within 2 weeks; the hydralazine-isosorbide combination provides equivalent neurohormonal benefit without the potassium-retaining RAAS effect
D) Add sodium polystyrene sulfonate (Kayexalate) 30 g twice daily as a long-term potassium management strategy alongside continued eplerenone 50 mg daily and lisinopril 10 mg daily; modern evidence has established that chronic Kayexalate therapy is safe and effective for long-term hyperkalemia management in HFrEF patients on dual RAAS blockade, with a favorable GI tolerability profile confirmed in the AMBER and DIAMOND trials
E) Hold empagliflozin because SGLT2 inhibitors paradoxically increase potassium in patients with eGFR below 45 mL/min/1.73m² by impairing distal tubule flow-mediated potassium excretion; removing empagliflozin will lower potassium by 0.5–0.8 mEq/L within 2 weeks in patients with CKD, restoring the target range without any change to eplerenone or lisinopril dosing

ANSWER: B

Rationale:

This patient has a compelling class I GDMT indication for eplerenone (EPHESUS: post-MI LV dysfunction with HF, on background ACE inhibitor and beta-blocker) and a confirmed potassium of 5.4 mEq/L that exceeds the guideline threshold for comfortable MRA continuation (below 5.0 mEq/L). The goal is to manage the potassium without sacrificing the survival benefit of eplerenone. The AMBER trial (Patiromer for Cardiorenal Risk Reduction in Patients With Resistant Hypertension and CKD) and the DIAMOND trial (patiromer enabling MRA therapy in HFrEF with CKD) specifically addressed this clinical problem: potassium binders — patiromer and sodium zirconium cyclosilicate (SZC) — reduce serum potassium by binding potassium in the gastrointestinal tract, and clinical trial evidence confirms they can enable MRA dose maintenance or re-titration in patients who develop hyperkalemia on MRA therapy. The appropriate strategy is to reduce eplerenone to 25 mg daily (to lower the acute hyperkalemia risk) while initiating a potassium binder, with the explicit plan to re-titrate eplerenone back to 50 mg once potassium is controlled — preserving the full GDMT dose. This approach — using potassium binders to enable GDMT continuation — has strong mechanistic rationale and clinical trial support.

Option A: Option A is incorrect: a confirmed potassium of 5.4 mEq/L is not an absolute contraindication requiring permanent eplerenone discontinuation; it is the threshold at which dose reduction and potassium binder initiation are appropriate, not the threshold for permanent cessation.
Option C: Option C is incorrect: replacing lisinopril with hydralazine-isosorbide dinitrate is a disproportionate intervention for hyperkalemia management; hydralazine-isosorbide is inferior to RAAS inhibition for HFrEF survival benefit and is specifically reserved for patients who genuinely cannot tolerate any RAAS inhibitor; removing lisinopril removes neurohormonal blockade that provides independent survival benefit alongside eplerenone.
Option D: Option D is incorrect: sodium polystyrene sulfonate (Kayexalate) is not appropriate for chronic long-term hyperkalemia management in HFrEF; it has a poor GI tolerability profile (constipation, sodium loading, rare intestinal necrosis), was not studied in the AMBER or DIAMOND trials (which used patiromer and SZC respectively), and is not endorsed as a chronic management strategy by modern HF guidelines.
Option E: Option E is incorrect: SGLT2 inhibitors do not paradoxically increase potassium in patients with eGFR below 45 mL/min/1.73m²; clinical trial evidence from EMPEROR-Reduced and DAPA-HF demonstrates that SGLT2 inhibitors reduce hyperkalemia rates in HFrEF including in patients with CKD — the mechanism is increased distal sodium delivery driving mild potassium excretion; removing empagliflozin would likely worsen rather than improve potassium in this patient.

11. A 74-year-old man with HFrEF is day 4 of IV furosemide 160 mg twice daily for acute decompensation. He has lost 8 kg. His JVP is now flat at 3 cm H₂O, blood pressure drops from 118/72 mmHg supine to 88/54 mmHg standing, mucous membranes are dry, and urine output has fallen to 15 mL/hour over the past 3 hours despite ongoing diuretic administration. Creatinine has risen from 1.0 to 1.9 mg/dL. A medical student asks: "Isn't this just acceptable worsening renal function during effective decongestion?" Which of the following best corrects the student's interpretation and explains how this presentation differs from acceptable WRF?

A) The student is correct that this represents acceptable WRF; a creatinine rise from 1.0 to 1.9 mg/dL (0.9 mg/dL) is within the range described in post-hoc analyses as acceptable WRF during effective decongestion; the 8 kg weight loss confirms effective fluid removal, and the flat JVP indicates that the target of euvolemia has been achieved; furosemide should be continued at the current dose to maintain the euvolemic state that has been established
B) The student's error is in the direction of the JVP interpretation: a flat JVP of 3 cm H₂O indicates persistent right heart failure with elevated right atrial pressure that is underestimated by the neck vein assessment; the correct interpretation is that the patient remains volume-overloaded despite the weight loss and that the creatinine rise reflects worsening cardiac output from persistent congestion — diuresis should be continued and intensified
C) The student is partially correct: the creatinine rise does represent acceptable WRF because the patient has achieved significant weight loss; however, the orthostatic hypotension is a separate finding from the renal issue and reflects autonomic dysfunction from his underlying HFrEF rather than volume depletion; the two findings should be addressed independently — continue diuresis for the renal acceptable WRF and initiate midodrine for the autonomic hypotension
D) The student is correct that the creatinine rise is acceptable WRF; however, the oliguria (15 mL/hour) indicates that a higher furosemide dose is needed to overcome the acute tubular resistance that develops on day 4 of continuous high-dose loop diuretic therapy; the appropriate response is to increase furosemide to 240 mg twice daily and add metolazone to restore urine output to the target range of 100–150 mL/hour
E) The student's interpretation is incorrect: this presentation has multiple features of true intravascular volume depletion from over-diuresis — flat JVP (3 cm H₂O), orthostatic hypotension (30 mmHg systolic drop on standing), dry mucous membranes, and oliguria (15 mL/hour) — which are signs of inadequate effective circulating volume to sustain renal perfusion pressure; acceptable WRF occurs during effective decongestion in a still-congested, hemodynamically stable patient, whereas this patient has been over-diuresed beyond euvolemia; furosemide should be held and clinical volume status reassessed before resuming diuresis at a lower dose

ANSWER: E

Rationale:

This question requires applying the clinical distinction between acceptable WRF and true renal ischemia from over-diuresis to a clinical scenario specifically designed to demonstrate the latter. The student's error is in applying the concept of "acceptable WRF" to a patient who has developed clear signs of intravascular volume depletion — the very scenario that defines when diuresis must stop. Acceptable WRF occurs when: creatinine rises modestly during effective decongestion, the patient remains hemodynamically stable, JVP is still elevated (volume overloaded), and there are no signs of hypoperfusion. In contrast, this patient demonstrates: flat JVP at 3 cm H₂O (below normal — indicating intravascular volume depletion below euvolemia, not volume overload); orthostatic hypotension with a 30 mmHg systolic drop on standing (a direct sign of inadequate effective circulating volume); dry mucous membranes (corroborating volume depletion); and oliguria of 15 mL/hour despite ongoing diuretic administration (renal hypoperfusion has reduced GFR to the point where tubular flow is insufficient to generate meaningful urine). The 8 kg weight loss and the flat JVP together confirm that decongestion has overshot euvolemia. The creatinine rise from 1.0 to 1.9 mg/dL in this context reflects true renal ischemia from over-diuresis, not acceptable WRF from appropriate decongestion. The correct response is to hold furosemide, reassess volume status clinically, allow spontaneous fluid reabsorption from the interstitium, and resume at a lower dose when the patient is stable and shows some return of JVP.

Option A: Option A is incorrect: the flat JVP, orthostatic hypotension, dry membranes, and oliguria are not signs of achieved euvolemia requiring maintenance — they are signs of over-diuresis requiring cessation; continuing furosemide at this point risks further acute kidney injury and hemodynamic deterioration.
Option B: Option B is incorrect: a flat JVP at 3 cm H₂O does not indicate hidden right heart failure with elevated pressure — it indicates low venous filling consistent with volume depletion; normal JVP is approximately 6–8 cm H₂O and 3 cm H₂O is below normal.
Option C: Option C is incorrect: orthostatic hypotension in this context is not autonomic dysfunction — it is a direct consequence of intravascular volume depletion from over-diuresis; treating it with midodrine while continuing furosemide would compound the injury.
Option D: Option D is incorrect: oliguria at 15 mL/hour in this clinical context is not a sign of "acute tubular resistance" requiring dose escalation — it is a sign of renal hypoperfusion from over-diuresis, and escalating furosemide would worsen the acute kidney injury.